A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable

Clinical and Experimental Immunology

Volumn 122, Issue 1, 2000, Pages 72-78

  Froebel, K S ^a   Raab, G M ^b   D'Alessandro, C ^a   Armitage, M P ^a   Mackenzie, K M ^b   Struthers, M ^b   Whitelaw, J M ^c   Yang, S ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

CD38; CD8; Clinical progression flow cytometry; HIV; Subpopulations

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS LOAD;

EID: 0033772067     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01348.x     Document Type: Article

References (44)

1. 6/l
2. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
3. T-cell subset alterations on HIV-infected homosexual men: NIAID multicenter AIDS cohort study
4. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: Staging and prognostic value
5. Activation and differentiation antigens on T cells of healthy, at-risk, and HIV-infected children
6. CD8+,CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients
7. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients
8. Epidemic of AIDS-related virus (HTLV-III/LAV) infection among intravenous drug abusers
9. World Health Organisation Acquired immune deficiency syndrome (AIDS): Interim proposal for a WHO staging system for HIV infection and disease
10. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections
11. Effect of CD4+ cell count measurement variability on staging HIV-1 infection
12. Phenotypically defined memory CD4+ cells are not selectively decreased in chronic HIV disease
13. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
14. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
15. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
16. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up
17. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity
18. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunode-ficiency virus type 1
19. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection
20. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: Findings from the Women and Infants Transmission Study
21. The Edinburgh City Hospital cohort: Analysis of enrolment, progression and mortality by baseline covariates
22. The molecular epidemiology of human immunodeficiency virus type 1 in six cities in Britain and Ireland
23. CD38+ CD8+ T cells as a marker of poor response to therapy in HIV-infected individuals
24. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration, and virologic end points
25. Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with >400 CD4+ lymphocytes per-microliter
26. Highly active antiretroviral therapy results in a decrease in CD8(+) T cell activation and preferential reconstitution of the peripheral CD4(+) T cell population with memory rather than naive cells
27. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection
28. Activation and cell cycle antigens in CD4(+) and CD8(+) T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection
29. Elevated CD38 antigen expression on CD8(+) T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4(+) cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression
30. Activated naive and memory CD4+ and CD8+ subsets in different stages of HIV infection
31. Isolation of a cDNA encoding human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation
32. CD38 molecule: Structural and biochemical analysis on human T lymphocytes, thymocytes and plasma cells
33. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP
34. The increased CD38 expressed by lymphocytes infected with HIV-1 is a fully active NADase
35. Functional B cell abnormalities in HIV type 1 infection: Role of CD40L and CD70
36. Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1
37. Modulation of lymphocyte interaction with endothelium and homing of HIV-1 gp120
38. Identification of cell subsets expressing intracytoplasmic cytokines within HIV-1-infected lymph nodes
39. Cell cycling in HIV infection: Analysis of in vivo activated lymphocytes
40. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens
41. Direct visualization of antigen-specific CD8(+) T cells during the primary immune response to Epstein-Barr virus in vivo
42. HLA-peptide tetrameric complexes
43. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: Comparison of statistical methods for measurement
44. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection